TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07136116: A Prospective, Real-World Study Evaluating the Impact of RISankizumab on BurdEn of Disease in Ulcerative Colitis in JaPan (RISE UP)

Sponsor: AbbVie · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,245,000

Rescue Site Savings

+$4,795,500

Unlock Full NCT07136116 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07136116 Rescue Dossier →